Fifth Third Bancorp lifted its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 52.3% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 145,756 shares of the biopharmaceutical company’s stock after purchasing an additional 50,075 shares during the period. Fifth Third Bancorp’s holdings in Halozyme Therapeutics were worth $16,091,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Bank of America Corp DE purchased a new stake in shares of Halozyme Therapeutics during the second quarter worth approximately $214,504,000. William Blair Investment Management LLC acquired a new stake in Halozyme Therapeutics in the second quarter valued at approximately $196,540,000. Congress Asset Management Co. lifted its stake in Halozyme Therapeutics by 85.6% in the third quarter. Congress Asset Management Co. now owns 2,281,615 shares of the biopharmaceutical company’s stock worth $251,890,000 after acquiring an additional 1,052,509 shares during the last quarter. Royal London Asset Management Ltd. lifted its stake in Halozyme Therapeutics by 12.4% in the second quarter. Royal London Asset Management Ltd. now owns 1,810,815 shares of the biopharmaceutical company’s stock worth $141,732,000 after acquiring an additional 200,262 shares during the last quarter. Finally, First Trust Advisors LP lifted its stake in Halozyme Therapeutics by 46.5% in the first quarter. First Trust Advisors LP now owns 1,482,340 shares of the biopharmaceutical company’s stock worth $95,804,000 after acquiring an additional 470,558 shares during the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.
Halozyme Therapeutics Stock Down 0.4%
HALO stock traded down $0.40 during trading on Friday, hitting $100.27. 2,276,239 shares of the company’s stock were exchanged, compared to its average volume of 2,352,912. The business has a 50-day moving average price of $114.56 and a two-hundred day moving average price of $85.51. The company has a current ratio of 3.88, a quick ratio of 3.60 and a debt-to-equity ratio of 13.50. The stock has a market capitalization of $11.43 billion, a price-to-earnings ratio of 25.51, a PEG ratio of 0.38 and a beta of 0.92. Halozyme Therapeutics, Inc. has a 52-week low of $61.22 and a 52-week high of $134.00.
Insider Activity at Halozyme Therapeutics
In related news, CEO Helen Torley sold 20,000 shares of the stock in a transaction on Thursday, October 8th. The shares were sold at an average price of $109.40, for a total value of $2,188,000.00. Following the transaction, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at $83,995,132. This trade represents a 2.54% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Matthew L. Posard sold 5,230 shares of the stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $108.54, for a total transaction of $567,664.20. Following the completion of the transaction, the director directly owned 53,609 shares in the company, valued at $5,818,720.86. This trade represents a 8.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 124,226 shares of company stock valued at $13,370,893 in the last 90 days. Insiders own 2.50% of the company’s stock.
Wall Street Analyst Weigh In
Several research firms have commented on HALO. Wells Fargo & Company boosted their price target on shares of Halozyme Therapeutics from $95.00 to $110.00 and gave the stock an “equal weight” rating in a report on Friday, November 6th. Wall Street Zen lowered shares of Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday, November 7th. Leerink Partners cut shares of Halozyme Therapeutics from an “outperform” rating to a “hold” rating and lifted their price objective for the stock from $110.00 to $117.00 in a research report on Friday, November 6th. Citigroup reaffirmed a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Friday, August 7th. Finally, Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st. Seven research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $108.18.
View Our Latest Stock Report on Halozyme Therapeutics
Halozyme Therapeutics Profile
Halozyme Therapeutics, Inc. is a biotechnology company focused on developing drug-delivery technologies and medicines. Its ENHANZE platform uses a recombinant human hyaluronidase enzyme, rHuPH20, to temporarily modify tissue under the skin and help enable the subcutaneous administration of certain biologic medicines that might otherwise require intravenous infusion. Halozyme licenses ENHANZE to pharmaceutical and biotechnology partners, which use the technology in their own products. The company also markets Hylenex recombinant, a hyaluronidase product used to facilitate the dispersion and absorption of other injected medicines and fluids.
Featured Articles
- Five stocks we like better than Halozyme Therapeutics
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
- Why Equinix and Digital Realty Benefit From Data Center Zoning Battles
- 3 GARP Plays That Could Offer a Better Balance as Markets Turn Volatile
Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report).
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
